#3736 SACUBITRIL/VALSARTAN IMPROVES THE VASCULAR ACCESS FLOW OF HEMODIALYSIS PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Abstract

Abstract Background and Aims Sacubitril/valsartan improved left ventricular systolic and diastolic function in patients with heart failure with reduced ejection fraction<40% (HFrEF) and end-stage kidney disease. However, there was no report concerning the effect of sacubitril/valsartan on access flow (Qa) of vascular access in maintenance hemodialysis (HD) patients with HFrEF. We aimed to investigate the effect of sacubitril/valsartan on Qa of vascular access in HD patients with HFrEF. Method We retrospectively screened the HD patients who received echocardiogram and Qa measurement in Taipei Veterans General Hospital and Cheng Hsin General Hospital from Jan. 2019 to Dec. 2021. Patients with HFrEF received twice of both echocardiography and Qa at 1 year apart were enrolled and divided into two groups, including those with or without the treatment of sacubitril/valsartan. The difference of Qa at baseline and 1 year later was compared by Wilcoxon signed-rank test, with a statistical significance of P<0.05. Results A total of 33 HD patients with HFrEF were analyzed with a mean HD vintage of 4.7 years. Sixteen patients received sacubitril/valsartan and the other 17 patients received conventional treatment. The mean Qa increased significantly from 633.8 to 948.8 mL/min (P<0.001) and the Qa change correlated with LVEF change [Fig. 1. correlation coefficient (r) =0.70, P=0.006] after 1-year treatment of sacubitril/valsartan; however, there was neither significant change of Qa (from 637.7 to 621.8 mL/min, P=0.44) nor correlation with LVEF change (Fig. 2, r=0.41, P=0.13) for controls after one year. Conclusion Sacubitril/Valsartan improves Qa in HD patients with HFrEF possibly related to the increase of LVEF.